0001157523-22-001569.txt : 20221109 0001157523-22-001569.hdr.sgml : 20221109 20221109073044 ACCESSION NUMBER: 0001157523-22-001569 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mirum Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001759425 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831281555 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38981 FILM NUMBER: 221370669 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-667-4085 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 8-K 1 a52964746.htm MIRUM PHARMACEUTICALS, INC. 8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 9, 2022

Mirum Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)

Delaware
001-38981
83-1281555
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
950 Tower Lane
Suite 1050
  
Foster City, California
  
94404
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 667-4085

N/A
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 

Title of each class
  
Trading
Symbol(s)
  

Name of each exchange on which registered
Common stock, par value $0.0001 per share
  
MIRM
  
Nasdaq Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒


Item 2.02 Results of Operations and Financial Condition.
 
On November 9, 2022, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2022. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
 

Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.

Exhibit
No.
  
Description
 
  
 
     
104
   Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Mirum Pharmaceuticals, Inc.
     
Date: November 9, 2022
By:
/s/ Christopher Peetz
   
Christopher Peetz
   
President and Chief Executive Officer


EX-99.1 2 a52964746ex99_1.htm EXHIBIT 99.1
Exhibit 99.1

Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

- Net product sales for LIVMARLI® (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date

- Mirum raises 2022 full year net product sales guidance estimate for LIVMARLI to $70 million

- Conference call to provide business updates today, November 9 at 5:00 a.m. PT/8:00 a.m. ET

FOSTER CITY, Calif.--(BUSINESS WIRE)--November 9, 2022--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

“The Mirum team achieved multiple key milestones on top of continued commercial growth this quarter, setting us up for a strong finish to 2022. We are well positioned for European approval by the end of the year with our recent positive CHMP opinion. Our revenues continue to grow in what has been an excellent rare disease launch,” said Chris Peetz, president and chief executive officer of Mirum. “Finally, our positive Phase 3 study results in PFIC validate our efficacy strategy across the highly burdensome cholestatic diseases we are studying.”

Key Operational Highlights

  • Announced positive topline data from LIVMARLI Phase 3 MARCH study in progressive familial intrahepatic cholestasis (PFIC).
  • Announced positive CHMP opinion for LIVMARLI for cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older.
  • Announced approval of LIVMARLI for cholestatic pruritus in patients with ALGS in Israel.
  • Presented key data at recent medical conferences, including:
    • NASPGHAN:
      • Six-year natural history comparison with LIVMARLI in ALGS.
      • Health-related quality of life impact on caregivers of children with ALGS.
      • Four-year growth improvement in ALGS with LIVMARLI.
    • The Liver Meeting of AASLD:
      • Oral late-breaker featuring MARCH PFIC data; selected as ‘Best of the Liver Meeting.’
      • Late-breaker poster highlighting safety and efficacy data for LIVMARLI from RISE infant safety study in ALGS.
      • Real-world evidence of LIVMARLI’s impact on patients with ALGS.
  • Bolstered balance sheet with public offering of common stock and net proceeds of $86.1 million.

Upcoming Anticipated Milestones

  • LIVMARLI
    • Anticipate European Commission decision regarding approval of LIVMARLI for the treatment of cholestatic pruritus in patients with Alagille syndrome two months of age and older, in the fourth quarter of 2022.
    • Topline data in the EMBARK Phase 2b clinical trial for biliary atresia in the second half of 2023.
  • Volixibat
    • Interim analysis for the VISTAS Phase 2b clinical trial for primary sclerosing cholangitis in mid-2023.
    • Interim analysis for the OHANA Phase 2b clinical trial for intrahepatic cholestasis of pregnancy in the first half of 2023.
    • Interim analysis for the VANTAGE Phase 2b clinical trial for primary biliary cholangitis in the second half of 2023.

Financial Results

  • Net product sales of LIVMARLI for the quarter ended September 30, 2022 were $18.8 million, compared to none for the quarter ended September 30, 2021.
  • Total operating expenses for the quarter ended September 30, 2022 were $51.7 million, compared to $47.8 million for the quarter ended September 30, 2021.
    • Research and development expenses for the quarter ended September 30, 2022 were $26.2 million, compared to $30.5 million for the comparable prior-year period. The decrease was primarily due to a decrease in collaboration funding for the terminated Vivet collaboration agreement offset by increased clinical trial expenses.
    • Selling, general and administrative (SG&A) expenses for the quarter ended September 30, 2022 were $22.5 million, compared to $17.4 million for the comparable prior-year period. SG&A investment increased in the third quarter of 2022 versus the third quarter of 2021, primarily due to personnel and other compensation related expenses as the company increased in size to support commercial activities for LIVMARLI and marketing and patient support expenses associated with commercial activities for LIVMARLI.
  • For the quarter ended September 30, 2022, Mirum reported a net loss of $35.7 million, or $1.02 basic and diluted net loss per share, compared with a net loss of $47.1 million, or $1.55 basic and diluted net loss per share, for the same period in 2021.
  • As of September 30, 2022, Mirum had cash, cash equivalents, restricted cash equivalents and investments of $285.3 million.

Business Update Conference Call

Mirum will host a conference call today, November 9, 2022 at 5:00 a.m. PT/8:00 a.m. ET, to provide business updates. Mirum will be joined by guest speaker Professor Richard J. Thompson, King’s College, London to discuss LIVMARLI and the results from the MARCH Phase 3 study. Join the call using the following details:

Conference Call Details:

U.S. toll-free:



1 844 200 6205

International:



1 929 526 1599

Passcode:



582604

You may also access the call via webcast and presentation materials by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.

About LIVMARLI® (maralixibat) oral solution

LIVMARLI® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older and is the only FDA-approved medication to treat cholestatic pruritus associated with Alagille syndrome. For more information, please visit LIVMARLI.com.

LIVMARLI is currently being evaluated in late-stage clinical studies in other rare cholestatic liver diseases including an open-label extension study in progressive familial intrahepatic cholestasis (PFIC), and in biliary atresia. LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.

IMPORTANT SAFETY INFORMATION

LIVMARLI can cause side effects, including:

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome and can worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your healthcare provider should do blood tests before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen) or loss of appetite.

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment.

Other common side effects reported during treatment were bone fractures and gastrointestinal bleeding.

Prescribing information

About Volixibat

Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver. Phase 1 and Phase 2 studies of volixibat demonstrated on-target fecal bile acid excretion, a pharmacodynamic marker of IBAT inhibition, in addition to decreases in LDL cholesterol and increases in 7αC4 which are markers of bile acid synthesis. Volixibat has been evaluated in more than 400 individuals across multiple clinical trials. The most common adverse events reported were mild to moderate gastrointestinal events observed in the volixibat groups.

Volixibat is currently being evaluated in Phase 2b studies for primary sclerosing cholangitis (VISTASPhase 2b clinical trial), intrahepatic cholestasis of pregnancy (OHANAPhase 2b clinical trial), and primary biliary cholangitis (VANTAGE Phase 2b clinical trial).

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. In Europe, the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for LIVMARLI for the treatment of cholestatic pruritus in patients with Alagille syndrome two months of age and older. A decision by the European Commission is expected by year-end 2022.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Mirum’s commercial performance for the remainder of the year; meeting the upcoming anticipated milestones, including a decision from the European Commission regarding approval of LIVMARLI for the treatment of cholestatic pruritus in patients with Alagille syndrome two months of age and older and the announcement of data from Mirum’s ongoing clinical trials; the regulatory approval path for its product candidates; and net product sales guidance estimate for LIVMARLI. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “continued,” “will,” “anticipate,” “expect,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, including the ongoing COVID-19 pandemic, instability in financial markets or the military conflict between Ukraine and Russia and related sanctions, and the other risks described more fully in Mirum’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Mirum Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations Data
(in thousands, except share and per share amounts)
(Unaudited)

 






 

 

Three Months Ended

 

Nine Months Ended


 

September 30,

 

September 30,


 

2022

 

2021

 

2022

 

2021


 






 
Revenue:







  Product sales, net

$

18,780

 


$

-

 


$

47,156

 


$

-

 


  License revenue

 

-

 


 

5,000

 


 

2,000

 


 

16,000

 


  Total revenue

 

18,780

 


 

5,000

 


 

49,156

 


 

16,000

 

Operating expenses:







  Cost of sales

 

2,932

 


 

-

 


 

7,880

 


 

-

 


  Research and development

 

26,217

 


 

30,471

 


 

75,737

 


 

103,653

 


  Selling, general and administrative

 

22,513

 


 

17,353

 


 

62,598

 


 

40,185

 


  Total operating expenses (1)

 

51,662

 


 

47,824

 


 

146,215

 


 

143,838

 

Loss from operations

 

(32,882

)


 

(42,824

)


 

(97,059

)


 

(127,838

)

Other income (expense):







  Interest income

 

1,352

 


 

72

 


 

1,714

 


 

301

 


  Interest expense

 

(3,971

)


 

(5,667

)


 

(11,620

)


 

(13,824

)


  Change in fair value of derivative liability

 

-

 


 

1,355

 


 

232

 


 

417

 


  Other (expense) income, net

 

(192

)


 

(35

)


 

953

 


 

(565

)

Net loss before for income taxes

 

(35,693

)


 

(47,099

)


 

(105,780

)


 

(141,509

)

Provision (benefit) for income taxes

 

13

 


 

9

 


 

(6,546

)


 

25

 

Net loss

$

(35,706

)


$

(47,108

)


$

(99,234

)


$

(141,534

)


 






 
Net loss per share, basic and diluted

$

(1.02

)


$

(1.55

)


$

(3.03

)


$

(4.68

)


 






 
Weighted-average shares of common stock outstanding, basic

 

34,927,790

 


 

30,367,727

 


 

32,809,365

 


 

30,250,127

 


 






 
Weighted-average shares of common stock outstanding, diluted

 

34,927,790

 


 

30,367,727

 


 

32,825,314

 


 

30,250,127

 


 






 

 






 

(1

)

  Amounts include stock-based compensation expense as follows:







 






 

  Research and development

$

2,517

 


$

3,035

 


$

7,519

 


$

7,792

 


  Selling, general and administrative

 

4,391

 


 

4,380

 


 

12,592

 


 

9,731

 


  Total stock-based compensation

$

6,908

 


$

7,415

 


$

20,111

 


$

17,523

 


 






 

 






 

 






 
Mirum Pharmaceuticals, Inc.
Selected Condensed Consolidated Balance Sheet Data
(in thousands)

 






 

 






 

 

September 30,

 

December 31,






 

2022

 

2021






 
(Unaudited)






 






 
Cash, cash equivalents, restricted cash equivalents and investments

$

285,347

 


$

261,524

 





Working capital

 

164,158

 


 

123,996

 





Total assets

 

364,347

 


 

294,651

 





Accumulated deficit

 

(356,393

)


 

(257,159

)





Total stockholders' equity

 

169,297

 


 

120,212

 





 

Contacts

Investor Contact:
Sam Martin
Argot Partners
ir@mirumpharma.com

Media Contact:
Erin Murphy
media@mirumpharma.com

EX-101.SCH 3 mirm-20221109.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mirm-20221109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 mirm-20221109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 09, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2022
Entity Registrant Name Mirum Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38981
Entity Tax Identification Number 83-1281555
Entity Address, Address Line One 950 Tower Lane
Entity Address, Address Line Two Suite 1050
Entity Address, City or Town Foster City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94404
City Area Code 650
Local Phone Number 667-4085
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Entity Central Index Key 0001759425
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol MIRM
Security Exchange Name NASDAQ
XML 7 a52964746_htm.xml IDEA: XBRL DOCUMENT 0001759425 2022-11-09 2022-11-09 false 0001759425 8-K 2022-11-09 Mirum Pharmaceuticals, Inc. DE 001-38981 83-1281555 950 Tower Lane Suite 1050 Foster City CA 94404 650 667-4085 false false false false Common stock, par value $0.0001 per share MIRM NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://mirumpharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a52964746.htm a52964746ex99_1.htm mirm-20221109.xsd mirm-20221109_lab.xml mirm-20221109_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a52964746.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "a52964746.htm" ] }, "labelLink": { "local": [ "mirm-20221109_lab.xml" ] }, "presentationLink": { "local": [ "mirm-20221109_pre.xml" ] }, "schema": { "local": [ "mirm-20221109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mirm", "nsuri": "http://mirumpharma.com/20221109", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a52964746.htm", "contextRef": "c20221109to20221109", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://mirumpharma.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a52964746.htm", "contextRef": "c20221109to20221109", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://mirumpharma.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001157523-22-001569-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-22-001569-xbrl.zip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